[Combined chemotherapy of experimental infection in neutropenia].
A significant decrease in resistance to infections caused by gramnegative pathogens was observed in mice with neutropenia induced by cytostatics. Efficacy of schemes for combined chemotherapy with beta-lactams, aminoglycosides and a novel peptide antibiotic was studied on model infections in mice with neutropenia. In the neutropenic mice with sepsis caused by Pseudomonas the peptide antibiotic administered parenterally in a single dose of 50 micrograms/kg provided high therapeutic activity. In combination with azlocillin, cefotaxime and amikacin the peptide antibiotic has a synergistic therapeutic action.
Viadro
M M
MM
Ivanitskaia
L P
LP
Samoĭlova
L N
LN
Kudinova
M K
MK
Bodunkova
L E
LE
D000380:Agranulocytosis / Q000276:immunology*; D000583:Amikacin / Q000008:administration & dosage*; D000818:Animals; D001390:Azlocillin / Q000008:administration & dosage*; D002439:Cefotaxime / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D007108:Immune Tolerance / Q000187:drug effects; D007710:Klebsiella Infections / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D051379:Mice; D009503:Neutropenia / Q000150:complications / Q000276:immunology*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology
D000583:Amikacin; D001390:Azlocillin; D002439:Cefotaxime
Kombinirovannaia khimioterapiia eksperimental'nykh infektsiĭ na fone neĭtropenii.